vildagliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 3642 274901-16-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • xiliarx
  • galvus
  • vildagliptin
  • jalra
  • NVP-LAF237
  • vildagliptin hydrochloride
  • vildagliptin HCl
A pyrrolidine-carbonitrile derivative and potent inhibitor of DIPEPTIDYL PEPTIDASE 4 that is used in the treatment of TYPE 2 DIABETES MELLITUS.
  • Molecular weight: 303.41
  • Formula: C17H25N3O2
  • CLOGP: 0.97
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 76.36
  • ALOGS: -2.24
  • ROTB: 3

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BA (Bioavailability) 85 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.03 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 9.90 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.89 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.67 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 60 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Sept. 26, 2007 EMA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 1098.77 23.58 217 4266 7127 63477412
Lactic acidosis 239.66 23.58 93 4390 38194 63446345
Acute kidney injury 133.02 23.58 125 4358 263290 63221249
Hypoglycaemia 108.92 23.58 62 4421 60003 63424536
Diabetes mellitus inadequate control 74.58 23.58 31 4452 15095 63469444
Dermatitis bullous 61.49 23.58 23 4460 8485 63476054
Crush syndrome 60.03 23.58 10 4473 119 63484420
Sensorimotor disorder 52.52 23.58 11 4472 475 63484064
Compartment syndrome 48.68 23.58 14 4469 2270 63482269
Hyperkalaemia 48.63 23.58 36 4447 54167 63430372
Drug interaction 47.57 23.58 69 4414 229062 63255477
Ketoacidosis 47.48 23.58 16 4467 4362 63480177
Glycosylated haemoglobin increased 46.65 23.58 21 4462 12377 63472162
Euglycaemic diabetic ketoacidosis 46.14 23.58 15 4468 3659 63480880
Diabetic ketoacidosis 44.90 23.58 24 4459 20481 63464058
Hyperglycaemia 44.90 23.58 31 4452 41836 63442703
Acute generalised exanthematous pustulosis 42.40 23.58 19 4464 11080 63473459
Shock 41.87 23.58 24 4459 23439 63461100
Blood glucose increased 36.87 23.58 37 4446 83719 63400820
Rhabdomyolysis 36.76 23.58 28 4455 43923 63440616
Language disorder 36.23 23.58 11 4472 2149 63482390
Pancreatitis acute 36.10 23.58 23 4460 27143 63457396
Capillary leak syndrome 36.03 23.58 11 4472 2189 63482350
Hyperparathyroidism secondary 35.81 23.58 10 4473 1457 63483082
Hyperphosphataemia 35.80 23.58 11 4472 2237 63482302
Altered state of consciousness 35.13 23.58 22 4461 25208 63459331
Hypomagnesaemia 34.92 23.58 23 4460 28714 63455825
Polymyalgia rheumatica 33.92 23.58 12 4471 3779 63480760
Cerebral infarction 33.68 23.58 21 4462 23872 63460667
Renal impairment 33.44 23.58 36 4447 88319 63396220
Hypoparathyroidism 33.00 23.58 8 4475 670 63483869
Blood phosphorus increased 32.16 23.58 11 4472 3134 63481405
Eosinophilia 32.07 23.58 20 4463 22736 63461803
Bladder sphincter atony 31.48 23.58 6 4477 159 63484380
Diabetic metabolic decompensation 29.93 23.58 9 4474 1701 63482838
Overdose 28.84 23.58 38 4445 115040 63369499
Urine ketone body present 26.56 23.58 9 4474 2494 63482045
Acetonaemia 26.25 23.58 5 4478 132 63484407
Cutaneous lupus erythematosus 25.85 23.58 9 4474 2703 63481836
Thrombocytosis 25.59 23.58 11 4472 5807 63478732
Drug reaction with eosinophilia and systemic symptoms 24.92 23.58 20 4463 33816 63450723
Thyroglobulin increased 23.90 23.58 4 4479 49 63484490
Inflammatory marker increased 23.88 23.58 11 4472 6828 63477711

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 881.43 20.47 215 5214 8451 34943051
Diabetes mellitus inadequate control 80.27 20.47 40 5389 13424 34938078
Hyperglycaemia 65.49 20.47 52 5377 39428 34912074
Cardiac failure 62.81 20.47 74 5355 91174 34860328
Hypoglycaemia 56.48 20.47 55 5374 54585 34896917
Acute kidney injury 53.42 20.47 134 5295 304854 34646648
Cerebral infarction 51.70 20.47 39 5390 27416 34924086
Euglycaemic diabetic ketoacidosis 50.63 20.47 19 5410 3203 34948299
Glycosylated haemoglobin increased 45.77 20.47 26 5403 11334 34940168
Ketonuria 41.39 20.47 11 5418 600 34950902
Drug interaction 38.11 20.47 98 5331 225848 34725654
Hyperkalaemia 37.65 20.47 50 5379 69339 34882163
Interstitial lung disease 36.90 20.47 48 5381 65234 34886268
Diabetic ketoacidosis 34.79 20.47 26 5403 18006 34933496
MELAS syndrome 32.62 20.47 6 5423 56 34951446
Lactic acidosis 32.20 20.47 33 5396 34739 34916763
Bone marrow oedema 31.23 20.47 9 5420 663 34950839
Pancreatic carcinoma 27.07 20.47 17 5412 8884 34942618
Orbital oedema 26.91 20.47 6 5423 155 34951347
Agnosia 25.74 20.47 5 5424 64 34951438
Intercepted medication error 24.48 20.47 7 5422 501 34951001
Anal incontinence 23.89 20.47 15 5414 7834 34943668
Ketoacidosis 23.50 20.47 12 5417 4231 34947271
Heart rate abnormal 22.38 20.47 9 5420 1822 34949680
Blister 21.71 20.47 22 5407 22836 34928666
Nervous system disorder 21.64 20.47 18 5411 14525 34936977
Acetonaemia 21.43 20.47 5 5424 159 34951343
Blister rupture 21.02 20.47 5 5424 173 34951329
Eosinophilia 20.92 20.47 23 5406 26199 34925303

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 1894.95 18.12 427 9498 14888 79719575
Lactic acidosis 216.75 18.12 125 9800 70234 79664229
Acute kidney injury 171.29 18.12 262 9663 519142 79215321
Hypoglycaemia 147.64 18.12 113 9812 101481 79632982
Diabetes mellitus inadequate control 116.58 18.12 58 9867 24206 79710257
Hyperglycaemia 108.24 18.12 81 9844 70254 79664209
Hyperkalaemia 90.48 18.12 90 9835 114308 79620155
Euglycaemic diabetic ketoacidosis 88.58 18.12 33 9892 6811 79727652
Cerebral infarction 84.87 18.12 59 9866 45617 79688846
Drug interaction 77.72 18.12 164 9761 415019 79319444
Diabetic ketoacidosis 75.19 18.12 49 9876 34073 79700390
Dermatitis bullous 68.25 18.12 34 9891 14211 79720252
Glycosylated haemoglobin increased 66.71 18.12 37 9888 19223 79715240
Ketoacidosis 60.31 18.12 26 9899 7828 79726635
Interstitial lung disease 55.16 18.12 69 9856 112531 79621932
Renal impairment 50.78 18.12 79 9846 157704 79576759
Eosinophilia 50.03 18.12 43 9882 45302 79689161
Crush syndrome 49.60 18.12 10 9915 198 79734265
Altered state of consciousness 49.26 18.12 42 9883 43780 79690683
Cardiac failure 44.99 18.12 74 9851 154768 79579695
Acetonaemia 44.64 18.12 10 9915 332 79734131
Toxicity to various agents 41.00 18.12 3 9922 421537 79312926
Ketonuria 40.71 18.12 12 9913 1196 79733267
Sensorimotor disorder 39.65 18.12 11 9914 883 79733580
Polymyalgia rheumatica 38.08 18.12 16 9909 4521 79729942
Urine ketone body present 34.78 18.12 14 9911 3551 79730912
Thrombocytosis 34.03 18.12 18 9907 8508 79725955
Pancreatitis acute 33.69 18.12 36 9889 49568 79684895
Blister rupture 33.66 18.12 9 9916 629 79733834
Blood glucose increased 33.45 18.12 55 9870 114920 79619543
Hypomagnesaemia 31.78 18.12 34 9891 46877 79687586
Pain 31.45 18.12 25 9900 703777 79030686
Rhabdomyolysis 30.90 18.12 50 9875 103081 79631382
Fatigue 30.42 18.12 43 9882 929684 78804779
Compartment syndrome 30.00 18.12 14 9911 5068 79729395
Bladder sphincter atony 29.38 18.12 6 9919 127 79734336
Diabetic metabolic decompensation 28.80 18.12 12 9913 3320 79731143
Cardiac failure acute 27.31 18.12 21 9904 18908 79715555
MELAS syndrome 26.70 18.12 6 9919 202 79734261
Language disorder 25.86 18.12 11 9914 3203 79731260
Joint swelling 25.53 18.12 3 9922 288643 79445820
Inflammatory marker increased 25.07 18.12 16 9909 10724 79723739
Bone marrow oedema 24.91 18.12 9 9916 1702 79732761
Headache 24.73 18.12 27 9898 653745 79080718
Hypoparathyroidism 24.70 18.12 8 9917 1090 79733373
Acute generalised exanthematous pustulosis 24.59 18.12 19 9906 17235 79717228
Hyperparathyroidism secondary 24.42 18.12 10 9915 2650 79731813
Pancreatic carcinoma 23.95 18.12 17 9908 13560 79720903
Capillary leak syndrome 23.75 18.12 11 9914 3914 79730549
Anal incontinence 23.72 18.12 19 9906 18149 79716314
Shock 23.43 18.12 28 9897 43520 79690943
Metabolic acidosis 23.35 18.12 39 9886 82490 79651973
Contraindication to medical treatment 23.34 18.12 8 9917 1298 79733165
Orbital oedema 22.41 18.12 6 9919 421 79734042
Cholangitis acute 22.09 18.12 8 9917 1524 79732939
Erythema multiforme 22.07 18.12 18 9907 17633 79716830
Hyperphosphataemia 21.39 18.12 12 9913 6364 79728099
Angina pectoris 21.11 18.12 29 9896 51703 79682760
Agnosia 20.89 18.12 5 9920 223 79734240
Drug reaction with eosinophilia and systemic symptoms 20.40 18.12 32 9893 64212 79670251
Toxic skin eruption 20.34 18.12 19 9906 22274 79712189
Arthralgia 20.12 18.12 25 9900 571778 79162685
Shock haemorrhagic 20.07 18.12 18 9907 20042 79714421
Cutaneous lupus erythematosus 20.01 18.12 9 9916 2994 79731469
Cardiac failure chronic 19.77 18.12 14 9911 11121 79723342
Nephrotic syndrome 19.73 18.12 14 9911 11160 79723303
Thyroglobulin increased 19.66 18.12 4 9921 83 79734380
Diabetes mellitus 19.50 18.12 35 9890 78355 79656108
Glycosuria 19.32 18.12 8 9917 2180 79732283
Neutrophilia 18.94 18.12 12 9913 7939 79726524
Infusion related reaction 18.92 18.12 3 9922 230234 79504229
Monoparesis 18.67 18.12 9 9916 3502 79730961
Hypophosphataemia 18.22 18.12 17 9908 19896 79714567

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BH02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Dipeptidyl peptidase 4 (DPP-4) inhibitors
MeSH PA D054873 Dipeptidyl-Peptidase IV Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D011480 Protease Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Dipeptidyl peptidase 4 Enzyme INHIBITOR Ki 8.52 CHEMBL DRUG LABEL
Dipeptidyl peptidase 8 Enzyme Ki 6.09 CHEMBL
Dipeptidyl peptidase 9 Enzyme Ki 7.17 CHEMBL
Prolyl endopeptidase FAP Enzyme IC50 5.43 CHEMBL
Dipeptidyl peptidase 9 Unclassified IC50 6.17 CHEMBL
Dipeptidyl peptidase IV Unclassified Ki 7.77 CHEMBL
Prolyl endopeptidase FAP Enzyme IC50 4.28 CHEMBL

External reference:

IDSource
D07080 KEGG_DRUG
C1570906 UMLSCUI
CHEBI:135285 CHEBI
CHEMBL142703 ChEMBL_ID
DB04876 DRUGBANK_ID
D000077597 MESH_DESCRIPTOR_UI
6918537 PUBCHEM_CID
6310 IUPHAR_LIGAND_ID
8399 INN_ID
924914-75-0 SECONDARY_CAS_RN
I6B4B2U96P UNII
596554 RXNORM
012358 NDDF
428611002 SNOMEDCT_US
428807006 SNOMEDCT_US
LF7 PDB_CHEM_ID

Pharmaceutical products:

None